Baxter Vasopressin in 0.9% Sodium Chloride Recall Over CGMP Deviations
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Baxter Healthcare Corporation is recalling specific lots of Vasopressin in 0.9% Sodium Chloride Injection due to CGMP deviations.
The full picture behind this FDA recall
This notice was issued by FDA on September 14, 2026 and geographically references United States. The FDA classifies this as a Class II recall, with the stated reason "CGMP Deviations", distributed us nationwide; puerto rico; and chile.. FDA recall classes run from I (reasonable probability of serious harm) to III (unlikely to cause harm), so the class number is the fastest way to gauge severity here. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
A quick skim tells you whether this affects you directly; a closer read tells you more. Check the scope, the source, and how recent the record is, then weigh it against related notices rather than treating any single one as a trend.
The original agency source is linked below so you can verify this record directly before acting on it. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Baxter Healthcare Corporation initiated a voluntary recall of Vasopressin in 0.9% Sodium Chloride Injection due to CGMP deviations.
Which Products Are Affected
The recall affects Vasopressin, in 0.9% Sodium Chloride Injection, 20 units per 100 mL (0.2 units/mL), 100mL Single-Dose Container, Rx only, Sterile, Baxter Healthcare Corporation, Deerfield, IL, 60012 USA, NDC 0338-9640-12. Affected lots include Lot # NC193672, NC193795 (Exp Date: 04/30/2028) and Lot # NC194198 (Exp Date: 05/31/2028). The recall number is D-0811-2026. Distribution was to US Nationwide, Puerto Rico, and Chile.
What You Should Do
Consumers and healthcare providers should refer to the FDA for further guidance on the ongoing recall.
Why This Matters
This Class II recall involves a prescription drug distributed nationwide and internationally.
Source
FDA recall D-0811-2026, https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Cardinal Health Presource Packs Recall Over CliniClean Pericare Wipes Contamination
FDA · September 14, 2026
Diagnostica Stago STA Staclot Protein S Recall Over QC Drift in Lot 273074
FDA · September 14, 2026
AVID Medical Halyard Convenience Kits Recall Over Endotoxin Variability in Neurological Sponges
FDA · September 14, 2026
Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (955 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to September 14, 2026.
Common Questions
What people usually ask about a notice like this one.